Prevalence of Fluoroquinolone-Resistant Clinical Isolates of Escherichia Coli in Urinary Tract Infection | ||
| Sohag Medical Journal | ||
| Article 40, Volume 22, Issue 1, January 2018, Pages 253-262 PDF (133.83 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/smj.2018.41769 | ||
| Authors | ||
| Laila Yousef1; Ashraf k Mohammed2; Ahmed M Mohamed2; Doha M Ali3 | ||
| 1Department of Clinical and Chemical pathology, Faculty of Medicine, Sohag University. | ||
| 2Department of Clinical Pathology, Faculty of Medicine, Sohag University. | ||
| 3Department of Clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University. | ||
| Abstract | ||
| Introduction: The commonest bacterial agent involved in causation of UTIs is Escherichia coli. The emergence of FQ resistant uropathogenic E. coli is of great concern. Aim of the work: to study resistance towards urinary E. coli with various generations of fluoroquinolones. Patients & Methods:: our study was carried out in the Clinical Pathology Department, Sohag University Hospital during the period from June 2016 to May 2017. Our study included 140 participants. Isolates from the specimens were obtained and identified using; Gram staining, colony characteristics on different culture medias. VITEC 2 Compact 15 identification kits were be used to confirm the identification of the isolates Results: E.coli was isolated from 100 patients (71%) of all patients complaining of UTI with positive urinary culture (study or case group). By studying prevalence of Antibiotic resistance of E.coli isolates reveals that fluoroquinolones show sensitivities of 42-46%. Also Nitrofurantoin has the highest sensitivity of 87%. This is followed by meropenem (67%). Ampicillin shows sensitivity in only 6% of cases. Regarding drug sensitivity in out & inpatients, we find that all generations of fluoroquinolones show highly significant resistance ratios among inpatients compared to outpatients. Meropenem show resistance more in inpatients than outpatients, with significant difference, Ampicillin and Nitrofuratoin show non-significant difference. Conclusion: our study show an increased fluoroquinolone resistance among uropathogenic E. coli isolates mainly in hospital admitted patients. | ||
| Keywords | ||
| Urinary tract infection (UTI); Escherichia coli and fluoroquinolone resistant E.coli | ||
|
Supplementary Files
|
||
| References | ||
|
1. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Annals of clinical microbiology and antimicrobials. 2007;6:4. 2. Ramakrishnan K, &, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. . Am Fam Physician, . 2005;71(5):933-42.. 3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infectious disease clinics of North America. 2014;28(1):1-13. 4. Gururaju T, Sarojamma V, &, Ramakrishna V. Prevalence and Fluoroquinolone Resistance Pattern in Escherichia coli Isolates of Urinary Tract Infection (UTI) Patients. . Journal of Krishna Institute of Medical Sciences (JKIMSU), . 2015;4(2). 5. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35(3):150-3. 6. Emody L, Kerenyi M, Nagy G. Virulence factors of uropathogenic Escherichia coli. International journal of antimicrobial agents. 2003;22 Suppl 2:29-33. 7. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ, et al. Fluoroquinolone-Resistant and Extended-Spectrum beta-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1). Emerging infectious diseases. 2016;22(9). 8. Somashekara SC, Deepalaxmi S, Jagannath N, Ramesh B, Laveesh MR, Govindadas D. Retrospective analysis of antibiotic resistance pattern to urinary pathogens in a Tertiary Care Hospital in South India. Journal of basic and clinical pharmacy. 2014;5(4):105-8. 9. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgraduate medicine. 2010;122(6):7-15. 10. Hwang TJ, Hooper DC. Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national crosssectional study. . J Antimicrob Chemother 2014;69(6): :1720-2. 11. Betitra Y, Teresa V, Miguel V, Abdelaziz T. Determinants of quinolone resistance in Escherichia coli causing community-acquired urinary tract infection in Bejaia, Algeria. Asian Pacific journal of tropical medicine. 2014;7(6):462-7. 12. Landry E, Sulz L, Bell A, Rathgeber L, Balogh H. Urinary Tract Infections: Leading Initiatives in Selecting Empiric Outpatient Treatment (UTILISE). The Canadian journal of hospital pharmacy. 2014;67(2):116-25. 13. Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, &, et al. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?. . Journal of Antimicrobial Chemotherapy. 2013;68(11): :2667-74. 14. Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrobial agents and chemotherapy, . 2012;56(4): :1680-5. 15. Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, et al. Urinary tract infection in adults: research priorities and strategies. International journal of antimicrobial agents. 2001;17(4):343-8. 16. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. The American journal of medicine. 2002;113 Suppl 1A:14S-9S. 17. Fagan M, Lindbaek M, Grude N, Reiso H, Romoren M, Skaare D, et al. Antibiotic resistance patterns of bacteria causing urinary tract infections in the elderly living in nursing homes versus the elderly living at home: an observational study. BMC geriatrics. 2015;15:98. 18. Grude N, Tveten Y, Kristiansen BE. Urinary tract infections in Norway: bacterial etiology and susceptibility. A retrospective study of clinical isolates. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2001;7(10):543-7. 19. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. European urology. 2008;54(5):1164-75. 20. Niranjan V, Malini A. Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. . Indian J Med Res 2014;139:945-48. 21. Saha S, Nayak S, Bhattacharyya I, Saha S, Mandal AK, Chakraborty S, et al. Understanding the patterns of antibiotic susceptibility of bacteria causing urinary tract infection in West Bengal, India. Frontiers in microbiology. 2014;5:463. 22. Mehta M, Dutta P, Gupta V. Antimicrobial susceptibility pattern of blood isolates from a teaching hospital in north India. Japanese journal of infectious diseases. 2005;58(3):174-6. 23. Alonso Sanz M, Abad Be´cquer M. Fenotipos de Resistencia en aislamientos urinarios de Escherichia coli en la comunidad: implicaciones terape´uticas. . Med Clin (Barc) 2003;120:361–4. 24. Kahlmeter G, Eco.Sens. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51(1):69-76. 25. Hasan AS, Nair D, Kaur J, Baweja G, Deb M, Aggarwal P. Resistance patterns of urinary isolates in a tertiary Indian hospital. Journal of Ayub Medical College, Abbottabad : JAMC. 2007;19(1):39-41. 26. Forbes B, Sahm D, and, Weissfeld AS. Infections of the Urinary tract, In; Baileys and Scott s (11thedt.) Diagnostic Microbiology St. Louis, Missouri, . Mosby. 2002:927-238. 27. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, L. Z. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex and location. BMC Infectious Diseases 2008;8. 28. Oteo J, Aracil B, Hoyo JF, Perianes J, Gomez-Garces JL, Alos JI. Do the quinolones still constitute valid empirical therapy for community-acquired urinary tract infections in Spain? Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 1999;5(10):654-6. 29. Goettsch W, van Pelt W, Nagelkerke N, Hendrix MG, Buiting AG, Petit PL, et al. Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. J Antimicrob Chemother. 2000;46(2):223-8. 30. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrobial agents and chemotherapy. 2002;46(8):2540-5. 31. Moreno E, Teresa P, Johnson R, A A. Quinolone, fluoroquinolone resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J Antimicrob Agents Chemother 2006;57(2)::204 –11. 32. Huang E, Stafford R. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. . Arch Intern Med 2002;162:41–7. | ||
|
Statistics Article View: 229 PDF Download: 257 |
||
